11 research outputs found
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis
IMPORTANCE:
Amyloid-ÎČ positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia.
OBJECTIVE:
To use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes.
DATA SOURCES:
The MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies.
STUDY SELECTION:
Case reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data.
DATA EXTRACTION AND SYNTHESIS:
Data were provided for 1359 participants with clinically diagnosed AD and 538 participants with non-AD dementia. The reference groups were 1849 healthy control participants (based on amyloid PET) and an independent sample of 1369 AD participants (based on autopsy).
MAIN OUTCOMES AND MEASURES:
Estimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) Δ4 status, using the generalized estimating equations method.
RESULTS:
The likelihood of amyloid positivity was associated with age and APOE Δ4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE Δ4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; nâ=â377) and to a lesser degree in APOE Δ4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; nâ=â593; Pâ<â.01). Similar associations of age and APOE Δ4 with amyloid positivity were observed in participants with AD dementia at autopsy. In most non-AD dementias, amyloid positivity increased with both age (from 60 to 80 years) and APOE Δ4 carriership (dementia with Lewy bodies: carriers [nâ=â16], 63% [95% CI, 48%-80%] at 60 years to 83% [95% CI, 67%-92%] at 80 years; noncarriers [nâ=â18], 29% [95% CI, 15%-50%] at 60 years to 54% [95% CI, 30%-77%] at 80 years; frontotemporal dementia: carriers [nâ=â48], 19% [95% CI, 12%-28%] at 60 years to 43% [95% CI, 35%-50%] at 80 years; noncarriers [nâ=â160], 5% [95% CI, 3%-8%] at 60 years to 14% [95% CI, 11%-18%] at 80 years; vascular dementia: carriers [nâ=â30], 25% [95% CI, 9%-52%] at 60 years to 64% [95% CI, 49%-77%] at 80 years; noncarriers [nâ=â77], 7% [95% CI, 3%-18%] at 60 years to 29% [95% CI, 17%-43%] at 80 years.
CONCLUSIONS AND RELEVANCE:
Among participants with dementia, the prevalence of amyloid positivity was associated with clinical diagnosis, age, and APOE genotype. These findings indicate the potential clinical utility of amyloid imaging for differential diagnosis in early-onset dementia and to support the clinical diagnosis of participants with AD dementia and noncarrier APOE Δ4 status who are older than 70 years
Diverse Applications of Nanomedicine
The design and use of materials in the nanoscale size range for addressing medical and health-related issues continues to receive increasing interest. Research in nanomedicine spans a multitude of areas, including drug delivery, vaccine development, antibacterial, diagnosis and imaging tools, wearable devices, implants, high-throughput screening platforms, etc. using biological, nonbiological, biomimetic, or hybrid materials. Many of these developments are starting to be translated into viable clinical products. Here, we provide an overview of recent developments in nanomedicine and highlight the current challenges and upcoming opportunities for the field and translation to the clinic. \ua9 2017 American Chemical Society
Utility of left lateral supine position for myocardial perfusion single-photon emission computed tomography compared with other methods of correcting inferior wall attenuation
Introduction Single-photon emission computed tomography (SPECT) myocardial perfusion imaging is an accepted method for reflecting the pathophysiological significance of lesions detected by coronary angiography. However, it has an inherent drawback in terms of false-positive perfusion defects for the inferior myocardial wall. To overcome this problem, different acquisition techniques have been proposed, including the computed tomographic-based attenuation correction method. In this respect, a new imaging technique, left supine lateral position SPECT myocardial perfusion imaging with technetium-99m methoxyisobutylisonitrile (Tc-99m MIBI), has been proposed to eliminate this problem and its value has been investigated in this report
A Europe-South America network for climate change assessment and impact studies
International audienceThe goal of the CLARIS project was to build an integrated European-South American network dedicated to promote common research strategies to observe and predict climate changes and their consequent socio-economic impacts taking into account the climate and societal peculiarities of South America. Reaching that goal placed the present network as a privileged advisor to contribute to the design of adaptation strategies in a region strongly affected by and dependent on climate variability (e. g. agriculture, health, hydro-electricity). Building the CLARIS network required fulfilling the following three objectives: (1) The first objective of CLARIS was to set up and favour the technical transfer and expertise in earth system and regional climate modelling between Europe and South America together with the providing of a list of climate data (observed and simulated) required for model validations; (2) The second objective of CLARIS was to facilitate the exchange of observed and simulated climate data between the climate research groups and to create a South American high-quality climate database for studies in extreme events and long-term climate trends; (3) Finally, the third objective of CLARIS was to strengthen the communication between climate researchers and stakeholders, and to demonstrate the feasibility of using climate information in the decision-making process. © Springer Science + Business Media B.V. 2009
Recommended from our members
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.
ImportanceAmyloid-ÎČ positron emission tomography (PET) imaging allows in vivo detection of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its diagnostic utility is still unclear because amyloid plaques also occur in patients with non-AD dementia.ObjectiveTo use individual participant data meta-analysis to estimate the prevalence of amyloid positivity on PET in a wide variety of dementia syndromes.Data sourcesThe MEDLINE and Web of Science databases were searched from January 2004 to April 2015 for amyloid PET studies.Study selectionCase reports and studies on neurological or psychiatric diseases other than dementia were excluded. Corresponding authors of eligible cohorts were invited to provide individual participant data.Data extraction and synthesisData were provided for 1359 participants with clinically diagnosed AD and 538 participants with non-AD dementia. The reference groups were 1849 healthy control participants (based on amyloid PET) and an independent sample of 1369 AD participants (based on autopsy).Main outcomes and measuresEstimated prevalence of positive amyloid PET scans according to diagnosis, age, and apolipoprotein E (APOE) Δ4 status, using the generalized estimating equations method.ResultsThe likelihood of amyloid positivity was associated with age and APOE Δ4 status. In AD dementia, the prevalence of amyloid positivity decreased from age 50 to 90 years in APOE Δ4 noncarriers (86% [95% CI, 73%-94%] at 50 years to 68% [95% CI, 57%-77%] at 90 years; nâ=â377) and to a lesser degree in APOE Δ4 carriers (97% [95% CI, 92%-99%] at 50 years to 90% [95% CI, 83%-94%] at 90 years; nâ=â593; Pâ<â.01). Similar associations of age and APOE Δ4 with amyloid positivity were observed in participants with AD dementia at autopsy. In most non-AD dementias, amyloid positivity increased with both age (from 60 to 80 years) and APOE Δ4 carriership (dementia with Lewy bodies: carriers [nâ=â16], 63% [95% CI, 48%-80%] at 60 years to 83% [95% CI, 67%-92%] at 80 years; noncarriers [nâ=â18], 29% [95% CI, 15%-50%] at 60 years to 54% [95% CI, 30%-77%] at 80 years; frontotemporal dementia: carriers [nâ=â48], 19% [95% CI, 12%-28%] at 60 years to 43% [95% CI, 35%-50%] at 80 years; noncarriers [nâ=â160], 5% [95% CI, 3%-8%] at 60 years to 14% [95% CI, 11%-18%] at 80 years; vascular dementia: carriers [nâ=â30], 25% [95% CI, 9%-52%] at 60 years to 64% [95% CI, 49%-77%] at 80 years; noncarriers [nâ=â77], 7% [95% CI, 3%-18%] at 60 years to 29% [95% CI, 17%-43%] at 80 years.Conclusions and relevanceAmong participants with dementia, the prevalence of amyloid positivity was associated with clinical diagnosis, age, and APOE genotype. These findings indicate the potential clinical utility of amyloid imaging for differential diagnosis in early-onset dementia and to support the clinical diagnosis of participants with AD dementia and noncarrier APOE Δ4 status who are older than 70 years